Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?
作者信息
Williet Nicolas, Roblin Xavier
机构信息
Department of Gastroenterology, University of Saint-Etienne, France.
Department of Hepatogastroenterology, University Hospital of Saint-Etienne, Allee Albert Raimond, 42270 Saint-Priest en Jarez, France.
出版信息
Therap Adv Gastroenterol. 2017 Jan;10(1):5-10. doi: 10.1177/1756283X16670074. Epub 2016 Oct 10.
Abstract
摘要
相似文献
1
Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?炎症性肠病患者中硫唑嘌呤单药治疗剂量减少的趋势：联合治疗情况如何？
Therap Adv Gastroenterol. 2017 Jan;10(1):5-10. doi: 10.1177/1756283X16670074. Epub 2016 Oct 10.
2
Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.硫唑嘌呤和5-氨基水杨酸类药物是否应在炎症性肠病中联合使用？：不良事件和结局的审计
Eur J Gastroenterol Hepatol. 2008 Mar;20(3):169-73. doi: 10.1097/MEG.0b013e3282f16d50.
3
Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.随机临床试验：一项比较低剂量硫唑嘌呤和别嘌醇与硫唑嘌呤对炎症性肠病临床结局疗效的初步研究。
Scand J Gastroenterol. 2016 Dec;51(12):1470-1475. doi: 10.1080/00365521.2016.1216589. Epub 2016 Aug 10.
4
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.优化的英夫利昔单抗单药治疗与优化的联合治疗同样有效，但在炎症性肠病中与更高的药物消耗相关。
Aliment Pharmacol Ther. 2019 Apr;49(7):880-889. doi: 10.1111/apt.15179. Epub 2019 Feb 19.
5
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.接受联合治疗的炎症性肠病患者硫唑嘌呤剂量减少：一项开放标签、前瞻性随机临床试验
Aliment Pharmacol Ther. 2017 Jul;46(2):142-149. doi: 10.1111/apt.14106. Epub 2017 Apr 27.
6
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.对病情缓解的克罗恩病患者停用免疫抑制剂或生物疗法。
Cochrane Database Syst Rev. 2018 May 12;5(5):CD012540. doi: 10.1002/14651858.CD012540.pub2.
7
Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.序贯联合治疗与单一疗法：对炎症性肠病相关手术时间无益处。
Dig Dis Sci. 2016 Nov;61(11):3261-3269. doi: 10.1007/s10620-016-4302-3. Epub 2016 Sep 17.
8
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.肿瘤坏死因子抑制剂与 COVID-19 合并免疫介导的炎症性疾病患者住院或死亡风险的相关性。
JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639.
9
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.硫嘌呤类药物或肿瘤坏死因子拮抗剂单独使用或联合使用与炎症性肠病患者淋巴瘤风险之间的关联
JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071.
10
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.阿达木单抗单药治疗及与硫唑嘌呤联合治疗克罗恩病：一项前瞻性随机试验
J Crohns Colitis. 2016 Nov;10(11):1259-1266. doi: 10.1093/ecco-jcc/jjw152. Epub 2016 Aug 26.
引用本文的文献
1
Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.低剂量硫唑嘌呤对诱导和维持活动性克罗恩病缓解有效：一项前瞻性观察性研究。
Medicine (Baltimore). 2018 Aug;97(34):e11814. doi: 10.1097/MD.0000000000011814.
2
De-escalation of Therapy in Inflammatory Bowel Disease.炎症性肠病治疗的降阶梯疗法
Curr Gastroenterol Rep. 2018 Jul 2;20(8):35. doi: 10.1007/s11894-018-0643-8.
本文引用的文献
1
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.接受联合治疗的炎症性肠病患者硫唑嘌呤剂量减少：一项开放标签、前瞻性随机临床试验
Aliment Pharmacol Ther. 2017 Jul;46(2):142-149. doi: 10.1111/apt.14106. Epub 2017 Apr 27.
2
Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry.低剂量硫唑嘌呤对维持激素依赖型溃疡性结肠炎的缓解有效：一项基于中国全地区人群的炎症性肠病登记研究结果
Therap Adv Gastroenterol. 2016 Jul;9(4):449-56. doi: 10.1177/1756283X16643509. Epub 2016 Apr 19.
3
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.硫唑嘌呤和6-巯基嘌呤用于维持溃疡性结肠炎的缓解
Cochrane Database Syst Rev. 2016 May 18;2016(5):CD000478. doi: 10.1002/14651858.CD000478.pub4.
4
Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia.实体器官移植中，医源性免疫抑制与非霍奇金淋巴瘤风险：澳大利亚一项基于人群的队列研究
Br J Haematol. 2016 Aug;174(4):550-62. doi: 10.1111/bjh.14083. Epub 2016 May 2.
5
NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.在日本炎症性肠病患者中，NUDT15 R139C相关的硫嘌呤白细胞减少症是由6-硫鸟嘌呤核苷酸非依赖性机制介导的。
J Gastroenterol. 2016 Jan;51(1):22-9. doi: 10.1007/s00535-015-1142-4. Epub 2015 Nov 21.
6
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.接受硫唑嘌呤治疗炎症性肠病患者患尿路癌的额外风险：一项前瞻性观察队列研究。
Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.
7
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.硫唑嘌呤或6-巯基嘌呤用于维持克罗恩病的缓解状态。
Cochrane Database Syst Rev. 2015 Oct 30;2015(10):CD000067. doi: 10.1002/14651858.CD000067.pub3.
8
NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.NUDT15 R139C在日本炎症性肠病患者中导致硫嘌呤诱导的早期严重脱发和白细胞减少。
Pharmacogenomics J. 2016 Jun;16(3):280-5. doi: 10.1038/tpj.2015.43. Epub 2015 Jun 16.
9
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.硫唑嘌呤与英夫利昔单抗联合治疗期间红细胞平均体积的变化与黏膜愈合相关：来自SONIC研究的事后分析
Inflamm Bowel Dis. 2015 Mar;21(3):606-14. doi: 10.1097/MIB.0000000000000302.
10
Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.在接受联合治疗的炎症性肠病患者中，6-硫代鸟嘌呤核苷酸的浓度与英夫利昔单抗的谷浓度相关。
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1118-24.e3. doi: 10.1016/j.cgh.2014.12.026. Epub 2015 Jan 3.
Zotero 插件